Thanks again to TheRad for putting my questions forward, I did ask the Co to allow remote dial in but they declined so really do appreciate your time to bring up these questions! Looking forward to hearing the answers.
Questions for the AGM.
1. With the Bioterm & Abcam agreements now in place, my understanding is we now have supply chain/mass production capabilities completed. Likewise, the company has stated we can use a generic CPT code for the LDT kit, this means the only remaining step to begin commercialisation in the U.S is a license agreement & KOL engagement/marketing. Has the company set a target date to secure a license agreement and if not, why? The highlighted part here is the most important question, the co has repeatedly said 'advanced discussions' for a number of months now so can they be more specific with a timeline on that? 2. Has the company considered applying for breakthrough device application, if not, why? * not valid anymore since we now know DeNovo is the way forward. 3. Renalytix has been making great progress in securing contracts with large hospital & insurance networks.With the cost difference aside, does the PIQ management team view KidneyIntelX as a competitor in this space? If not, why? 4. Is Janssen still collaborating in the additional studies there were mentioned from the Ph2 conclusion? 5. What is the price of the PromarkerD test in Italy?
PIQ Price at posting:
$1.12 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)